

Index

- A-band 5, 59, 128
 AAA proteases 378
 AC133+ cells 32–33
 ACADVL gene defects 404
 acetazolamide 412, 419, 420–421
 acetazolamide-responsive myotonia 412
 acetylcholine (ACh) 453
 acetylcholine receptors (AChR) 453
 autoantibodies 48, 453–454
 clustering 45–46, 52, 463
 gene mutations 47, 463–464
 inherited deficiency 47, 463–464
 localization 3, 4, 46
 acetylcholinesterase (AChE) 4–5
 endplate deficiency 461–463, 467
 inhibitors, *see* anticholinesterases
 N-acetylmannosamine (ManNAc) 493, 495
 acid maltase, *see* α -glucosidase
 acid phosphatase 101
 acquired myopathies 183, 191
 acromegaly 473
 actin 59
 accumulation 106–107, 118, 134
 ACTA-1 mutations 60, 289–290
 cytoplasmic γ - 62
 filamentous (F-actin) 3, 59, 128
 filaments 3, 5
 immunohistochemistry 103, 106–107
 myosin crosslinking 3, 59
 actin aggregate myopathy 129, 290
 alpha-actinin 3, 61
 acute quadriplegic myopathy (critical illness myopathy) 130, 477
 acyl-CoA dehydrogenase 9 (ACAD9) deficiency 397, 399, 405
 Addison disease 472
 adenine nucleotide translocase (ANT1) 380
 adeno-associated virus (AAV) vectors 197
 adenosine triphosphate, *see* ATP
 adenovirus vectors 197
 adipose tissue, increased 95, 96
adr mouse 410–411
 adrenal myopathies 472
 adult polyglucosan body disease 396
 age of onset 183, 184
 age-related motor-unit remodeling 500
 aging 499–500
 impaired muscle regeneration 28
 mitochondrial changes 140
 neurogenic muscle atrophy 500
 sarcopenia of 499–500
 satellite cells 30
 agrin 4–5, 52–53, 463
 AChR clustering 45–46, 52
 mini-agrin 52, 53
 neural and muscle isoforms 52–53
 alanine transaminase (ALT) 186
 alcohol abuse 475, 478–480, 503
 alcoholic myopathies 478–480, 503
 aldolase A deficiency 396
 Alpers–Huttenlocher syndrome (AHS) 370, 371, 379
 alpha motor neurons 1–2
 amino acid metabolism 70
 amiodarone 478
 ammonia 394
 amphotericin B 478
 amphiphysin-2 (BIN1) 55, 294
 amyloid myopathy 147, 503
 amyotrophic lateral sclerosis (ALS) 108
 Andersen disease, *see* brancher deficiency
 Andersen–Tawil syndrome (ATS) 415, 416–417
 diagnosis 417–418
 molecular basis 59, 416
 treatment 419
 see also periodic paralysis
 anesthesia
 myasthenia gravis 481–482
 myasthenic complications 481
 nondystrophic myotonias 412–413
 past history 175–176
 periodic paralyses 419
 see also malignant hyperthermia
 ANT1 mutations 380
 anti-Jo antibodies 437
 antibiotics 479, 481–482
 anticholinesterases 457, 459, 461, 501
 congenital myasthenic syndromes 467
 diagnostic testing 457
 drug-induced myasthenia 481
 anticipation, genetic 349–350
 antimalarial drugs 478
 apoptosis 147, 214
 arm levitation phenomenon 443
 arthrogryposis, distal 60, 283–284, 290
 arthrogryposis multiplex congenita 455
 aspartate transaminase (AST) 186
 ataxia and epilepsy, autosomal recessive 371
 ATP, generation 67, 365, 390
 ATP6 mutations 367
 ATP12 mutations 377
 ATPase 97–98, 116
 atrophy, muscle 29
 electron microscopy 143, 144
 fiber-type specific 100–101
 histopathology and immunoanalysis 95, 99, 108
 neurogenic aging-related 500
 autophagic vacuolar myopathies
 adult onset 56
 drug-induced 478
 infantile 56
 X-linked congenital 56
 autophagic vacuole proteins 55
 autophagic vacuoles with sarcolemmal features (AVSFs) 56
 axial myopathy (camptocormia) 167–168
 azathioprine 446–447, 457
 B cells 439
 B7 costimulatory molecules 439
 B17.2L (NDUFA12L) 377–378
 bacterial myositis 442
 barrier-to-autointegration factor (BAF) 64
 Barth syndrome 380
 basal lamina 4–5, 48, 142–143
 basophilia 96
 Becker muscular dystrophy (BMD) 205–206
 carriers, *see* dystrophinopathy carriers
 diagnosis 215–220
 genetic counseling 221–222
 molecular basis 42–43, 206–213
 molecular testing 218–220
 MRI 152
 muscle biopsy 215–217
 histo- and cytochemistry 109–110, 216–217, 218
 immunoblotting 107, 217
 light microscopy 101, 108–111
 secondary protein defects 110
 pathogenesis of myofiber damage 213–215
 see also dystrophinopathies

Index

- Becker myotonia 57, 409–410
- bedside diagnosis 163
- benign acute childhood myositis (BACM) 444
- beta (skeleto-fusimotor) motor neurons 1–2
- Bethlem myopathy (BM)
268–269, 299–300,
307–310
clinical features 301, 308
diagnosis 309–310
future perspectives 310–311
genetic counseling 310
genotype–phenotype
correlations 308–309
histopathology and
immunoanalysis 117,
270, 309
management 310
molecular basis 48–50, 307–308
MRI 157, 158, 309
- bicycle exercise test 187–188,
394, 395
- BINI* gene mutations 55, 294
- biochemical basis of disease 37–72
- biochemical tests 186–187
- biopsy 94
enzyme assays 187
muscle, *see* muscle biopsy
- Bjornstad syndrome 377
- blood vessel-associated cells
32–33, 199
- blood vessels
electron microscopy 144–145
see also capillaries
- bone marrow-derived cells 32
- bone marrow pancreas (Pearson)
syndrome 370
- botulism 86, 87
- brain involvement, *see* central
nervous system (CNS)
involvement
- brancher deficiency 137, 139, 396
- branching enzyme 67
- Brody disease 71, 171
- Brody syndrome 71
- BSC1L* mutations 377
- cachexia 29, 500
- calcium
glycogen degradation 67
mediated damage in
dystrophinopathies 214
- calcium channels, voltage-gated
(VGCCs) 3, 56–57, 58
autoantibodies 48, 458
- gene (*CACNA1S*) mutations
58, 415, 417–418
neuromuscular junction 453
- calcium release junctions,
see triads
- calpain(s) 214, 240
- calpain-3 (p94) 240
gene mutations 61, 239–240
protein interactions 53, 327
- calpainopathy (LGMD2A)
239–241
clinical features 239
diagnosis 240–241
genotype–phenotype
correlations 240
immunoblotting 107, 240
management 241
molecular basis 61, 239–240
MRI 152–153, 154
pathology 107, 111, 240
- camptocormia 167–168
- cancer, *see* malignant disease
- cap disease 60, 290
electron microscopy 129–130
histopathology and
immunoanalysis 120, 288
- capillaries
depletion 124, 144, 146
electron microscopy 144–145
pipe-stem 144, 443
- carbenoxolone 478
- carbohydrate metabolism 67, 68
disorders of 391–396
- carbonic anhydrase inhibitors 419
- carcinomatous myopathy 500–501
- cardiac involvement, *see* heart
disease
- cardiolipin 364, 365
abnormalities 380
- cardiomyopathic hamster
(CMH) 41
- cardiomyopathy
cysteine-rich protein 3
(CSR3) mutations 61
dystrophinopathies 205–206,
220
mitochondrial disorders 381
myofibrillary myopathies 490
telethonin mutations 245
tropomyosin mutations 60
X-linked dilated, *see* X-linked
cardiomyopathy
- carnitine
primary deficiency,
see carnitine transporter
deficiency
secondary deficiency 402
supplements 402, 406–407
- carnitine:acylcarnitine
translocase (CACT)
deficiency 69, 399, 405
- carnitine palmitoyl-transferase
(CPT) 69, 402–403
- carnitine palmitoyl-transferase I
(CPT-I) deficiency 399, 405
clinical features 397, 402
muscle biopsy 122
- carnitine palmitoyl-transferase II
(CPT-II) deficiency 399,
402–403
clinical features 397, 403
muscle biopsy 122, 140, 402
- carnitine transporter deficiency
(primary carnitine
deficiency) 397, 402,
406–407
molecular basis 69, 399
muscle biopsy 122, 140, 141, 402
- cataracts
congenital muscular dystrophy
with 276
myotonic dystrophy 356
- catch property 12, 13
- cats, muscular dystrophy 43
- caveolae 54
- caveolin-3 54, 211
dysferlin interaction 53, 334–335
gene mutations,
see caveolinopathies
overexpression 54, 211
- caveolinopathies 54
distal phenotype 158, 237
LGMD presentation 237
phenotypes 211, 237
- CCTG repeats 350, 353
- CCUG RNA repeats 353
- CD133+/AC133+ cells 32–33
- cell therapy 30–33, 196
blood vessel-associated cells
32–33, 199
markers to track donor cells 32
- central core disease (CCD) 292
malignant hyperthermia
289, 293
molecular basis 70–71, 292
MRI 156
muscle pathology 112, 119,
131, 132, 288
- central nervous system (CNS)
involvement 174
 α -dystroglycanopathies 258, 260
examination 177
laminin- α 2 deficiency 263
myotonic dystrophy 355
peripheral nerve
hyperexcitability
syndromes 460
- centronuclear myopathy,
see myotubular/
centronuclear myopathies
- cerebellar atrophy, congenital
muscular dystrophy
with 276
- channelopathies, *see* ion
channelopathies
- CHAT, *see* choline
acetyltransferase
- chemokines 439
- children
inflammatory myopathies
444–445
muscle examination 182–183
- chloride channels 57–58
ClC-1 splicing 351–352
gene (*CLCN1*) mutations 57–58,
410–411
- chloroquine-induced myopathy
56, 136, 137, 478
- cholesterol-lowering agent
myopathies (CLAM) 168,
476–477
- choline acetyltransferase (*CHAT*)
gene mutations 46, 461,
462, 465, 466, 467
- chorionic villus samples 94
- CHRNE* gene mutations 462,
463–464, 465, 466
- CHRNA* gene mutations 463
- chronic fatigue syndrome 168
- chronic progressive external
ophthalmoplegia (CPEO)
368
- classification 189–193
age of onset 183, 184
hereditary/acquired distinction
183, 191
predominant patterns of
weakness 164–168
proposed system (Brooke) 190
simple system 183, 193
- clinical assessment 163–189
- clofibrate 476
- Coat disease 318, 319
- coenzyme Q (CoQ) 365
deficiency 380, 405
oral supplements 381–382
- cofilin-2 60, 289–290
- colchicine 478
- cold-sensitive myotonia 411–412
- collagen
fibers 4–5
immunohistochemistry 105
overproduction, *see* fibrosis

- collagen vascular diseases,
see connective tissue disorders
- collagen VI 48–50, 269–271, 303, 307–308
gene defects 49, 50, 271–272, 307
immunohistochemistry 105, 107, 115, 117, 270, 309
- collagen-VI-related myopathies 268–273, 307–310
clinical features 271, 301, 308
diagnosis 269, 272, 309–310
genetic counseling 310
genotype–phenotype correlations 271–272, 308–309
management 272–273, 310
molecular basis 48–50, 269–271, 307–308
transitional phenotypes 271
see also Bethlem myopathy, Ullrich congenital muscular dystrophy
- COLQ gene mutations 46, 461–463, 465, 466
- complex repetitive discharges (CRDs) 83
- compound muscle action potentials (CMAPs) 81, 82, 85–87, 89
- computed tomography (CT) 151, 188
- congenital fiber type disproportion (CFTD) 288, 292
actin mutations 60
histopathology and immunoanalysis 116, 120
selenoprotein-1 mutations 71
tropomyosin mutations 60
- congenital inflammatory myopathy 445
- congenital muscular dystrophies (CMD) 257–276
with adducted thumbs 274
 α -dystroglycan glycosylation and other membrane receptor defects 257–262
with cataracts 276
with cerebellar atrophy 276
classification 257
extracellular matrix protein defects 114–115, 263–273
histopathology and immunoanalysis 95, 105, 107–108, 109, 113–116
with joint hyperlaxity, autosomal recessive 273
MRI 154
nuclear protein defects 273–274
sarco/endoplasmic reticulum protein defects 115–116, 274–276
- with short stature, mental retardation and distal laxity 276
type 1A (MDC1A), see laminin- α 2 deficiency
type 1B (MDC1B) 276
type 1C (MDC1C; FKRP-related) 246–247, 257–262
type 1D (MDC1D; LARGE-related) 39, 257–262, 258–259
- congenital myasthenic syndromes (CMS) 46–48, 460–468
clinical features 460–461, 462, 466
diagnosis 465–467
genetic counseling 467
genotype–phenotype correlations 465
management 467
postsynaptic 460, 463–465
presynaptic 460, 461
slow-channel, see slow-channel syndrome
synaptic basal lamina-associated 460, 461–463
- congenital myopathies 282–295
classification 282, 283
clinical features 282–284
diagnosis 284–285, 291
differential diagnosis 285, 289
genetic counseling 289
genotype–phenotype correlations 284, 287
imaging 156–157, 285
management 285–289
molecular basis 282, 283
muscle biopsy 118–120, 285
with no known genes 284, 294
with unusual structures 120
- connective tissue disorders 504–505
inflammatory myopathies 442
muscle pathology 124, 144
- connective tissue proliferation, see fibrosis
- Conn syndrome 472
- contractures 168–169, 170, 171, 299
collagen VI-related myopathies 308, 310
Emery–Dreifuss muscular dystrophy 305
- core myopathies 70–71, 292–293
electron microscopy 131, 132
histopathology and immunoanalysis 118–119
- corticosteroid therapy
Duchenne muscular dystrophy 220–221
- inflammatory myopathies 445–446
myasthenia gravis 457
sarcoidosis 505
steroid myopathy 475–476
- costameres 62, 208–209
- costimulatory molecules 439
- COX, see cytochrome *c* oxidase
- COX6B1 mutation 377
- COX10 mutations 377
- COX15 mutations 377
- coxsackieviruses 441
- cramp-fasciculation syndrome (C-F) 459–460
- cramps 169
drug-induced 474
- cranial nerve innervated muscles, strength assessment 178–180
- creatine kinase (CK), serum 186
- creatine supplements 382
- critical illness myopathy (CIM) (acute quadriplegic myopathy) 130, 477
- Crohn disease 442
- α B-crystallin 63
gene (*CRYAB*) mutations 486
- α B-crystallinopathy 63
clinical features 484–485
muscle imaging 489
muscle pathology 486
- CTG repeats 348–350
- CUG-binding protein 1 (CUGBP1) 66, 352
- CUG RNA repeats 350–352
- Cushing syndrome/disease 472
- cycle ergometry 187–188, 394, 395
- cyclophilin D 214
- cyclophosphamide 446, 457
- cyclosporin
collagen VI-related disorders 50, 270–271, 311
inflammatory myopathies 446
myasthenia gravis 457
- cysteine-rich protein 3 (CSRP3) 61
- cytochrome *c* 365
- cytochrome *c* oxidase (COX)
fiber typing 96, 97–98
isolated deficiency 377
mitochondrial disorders 98, 99, 122–123, 374
- cytokines 439
- cytoplasmic bodies 131, 133
- cytoskeleton, muscle fiber 3, 61–64
- Danon disease 294
molecular and biochemical basis 56
muscle biopsy 122, 135–136
- debrancher deficiency 395–396
- debrancher enzyme 67, 69
- dendritic cells 439
- denervation 13–14
electron microscopy 143, 144
EMG features 83
histopathology and immunoanalysis 95, 108
satellite cell changes 29
- deoxyguanosine kinase (DGUOK) 379
- dermatomyositis (DM) 427
childhood 428, 433, 444
clinical features 427–428, 430
diagnosis 431–435
drug-induced 478
electron microscopy 134, 143, 144, 146, 147
extramuscular features 430–431
immunopathogenesis 435–437
malignant disease 430–431
MRI 159–160
muscle pathology 99, 100, 123–124, 431–435, 436
sine myositis 428
skin rash 175, 176, 428
treatment 445–447
- dermomyotome 20
- desmin 3–4, 63
mutations 486
satellite cells 23
- desminopathies 63, 331–332
clinical features 484
muscle imaging 159, 489
muscle pathology 486
- developmentally regulated proteins 102–103
- DGUOK mutations 379
- diabetes mellitus 473
angiopathy 144, 146
thigh muscle infarction 188, 473
- diagnosis
bedside 163, 164
initial differential 183
- diagnostic testing 163, 164, 183–189
- 3,4-diaminopyridine (DAP) 459, 467, 501
- dichloroacetate 382
- dichlorphenamide 419
- 2,4-dienoyl-CoA reductase deficiency 397, 399, 405

Index

- dietary management
fatty acid oxidation defects 403, 404, 406–407
mitochondrial disorders 381–382
periodic paralysis 418
- differential diagnosis, initial 183
- dimethylglycine 382
- diplopia 167, 455–456
- distal anterior compartment myopathy 53
- distal arthrogryposis 60, 283–284, 290
- distal hereditary motor neuropathy 56
- distal myopathies 54, 323–337, 492
adult onset dominant (MPD3) 337
caveolinopathies 158, 237
classification 323, 324
early adult dominant 337
location of proteins involved 323, 325
MRI 157–159
myopathies with distal phenotypes 325, 337
with respiratory failure 337
type 1 (MPD1), *see* Laing myopathy
vocal cord and pharyngeal (VCPDM; MPD2) 337
see also specific myopathies
- distal myopathy with rimmed vacuoles (DMRV; Nonaka myopathy) 333–334
molecular basis 56, 333–334, 492
pathology 137, 334
- distal myotilinopathy 159, 330–331
- distal nebulin myopathy 158, 290–291, 336
- distal neuromyopathy, dominant 337
- distal pattern of weakness, predominantly 164–166, 195
- distal upper/proximal lower extremity weakness 166, 195
- disuse 13, 29, 500
- diuretics 478
- DMPK gene and protein 347, 350–351
- DNA mismatch repair proteins 348
- docosahexaenoic acid 404, 406
- dogs, muscular dystrophy 43, 211
- Dok-7 45–46, 464
- DOK7 gene mutations 47–48, 462, 464–465, 466
- dominant diseases, molecular therapies 200
- dominant negative effects 200
- dropped head syndrome 167–168
- drug history 176
- drug-induced myasthenic syndromes 479, 480–482
clinical presentations 480–481
identification 481
management 481–482
mechanisms 481
- drug-induced myopathies 473–482
autophagic 478
clinical syndromes 474–475
hypokalemic 478
inflammatory 428, 443–444, 478
mitochondrial 477–478
painful 168, 169, 474
painless 176, 475
- drugs of addiction 475
- Duchenne muscular dystrophy (DMD) 205
animal models 43, 211
carriers, *see* dystrophinopathy carriers
cell therapy 30–31, 32–33, 221
cytogenetic analysis 217–218
diagnosis 215–220
genetic counseling 221–222
impaired muscle regeneration 28, 215, 216
mimics 206
molecular basis 42–43, 54, 206–213
molecular testing 218–220
molecular therapies 197–200, 221
MRI 152, 153
muscle biopsy 213, 215–217
electron microscopy 143, 147, 211
histo- and cytochemistry 103–104, 109–110, 216–217
histology 95, 101, 108–111
immunoblotting 217
light microscopy 216
secondary protein defects 110, 216–217
pathogenesis of myofiber damage 213–215
preimplantation diagnosis 222
prenatal diagnosis 94, 222
therapy 220–221
see also dystrophinopathies
- DUX4 317
- dynammin-2 (DNM-2) 55, 293
- dysferlin 53–54, 242, 334–335
- dysferlinopathies 241–242
clinical features 241–242, 335
diagnosis 242, 334, 335
- distal phenotype, *see* Miyoshi myopathy
- genotype–phenotype correlations 335
- LGMD2B presentation 241–242
management 242, 335
molecular basis 53, 242
mouse models 53–54, 335
pathology 111, 112
- dysphagia 175
inflammatory myopathies 430
oculopharyngeal muscular dystrophy 341, 344
- dystrobrevin 43–44
- dystroglycan(s) 4–5, 40, 209
complex 37–40
immunoblot analysis 107–108, 115
immunohistochemistry 102, 105, 109, 110, 115
laminin binding 42, 51
- α -dystroglycan 37, 247
glycosylation 37–38, 40
glycosylation defects, *see* α -dystroglycanopathies
- β -dystroglycan 37, 247
- α -dystroglycanopathies 209, 246–249, 257–262
animal models 39–40
clinical features 246–247, 259–261
diagnosis 248, 258–259, 261–262
future therapies 40, 262
genetic counseling 262
genotype–phenotype correlations 247–248, 261
histopathology and immunoanalysis 115, 259, 261
LGMD2I presentation 245, 246–249
LGMD2K, 2M and 2N presentations 248–249
management 248, 262
molecular basis 38–40, 247, 259
- dystrophia myotonica, *see* myotonic dystrophy
- dystrophin 3, 41–43, 208–212
deficient mouse, *see mdx* mouse
function 42, 209
functional partners 39, 208–212
gene 41, 206–207
mRNA transcript manipulations 198
mutations 42–43, 191, 209, 212–213
promoters 41–42, 207–208
replacement therapy 197–198, 212
immunoblotting 107, 217
- immunohistochemistry 103–104
dystrophinopathies 101, 109–110, 216, 217
dystrophinopathy carriers 101, 110, 217, 219
females with Xp21 translocations 111
secondary defects 104
X-linked cardiomyopathy 111
isoforms 41–42, 207–208
related proteins 44–45, 207
structure 42, 207
- dystrophin-associated glycoprotein complex (DGC) 37–45, 210
dystrophinopathies 209–211, 217
immunohistochemistry 104, 110
transgenic mouse studies 212
- dystrophinopathies 205–222
animal models 43, 211
diagnosis 215–220
electrodiagnostic testing 215
genetic counseling 221–222
history 205
microscopy of muscle biopsies 108–111
molecular background 206–213
molecular testing 218–220
pathogenesis of myofiber damage 213–215
phenotypes 205–206
serum creatine kinase 215
therapy 220–221
see also Becker muscular dystrophy; Duchenne muscular dystrophy
- dystrophinopathy carriers 206
genetic counseling 221–222
immunohistochemistry 101, 110, 217, 219
MRI 152
serum creatine kinase 215
- ecsit 377
- edrophonium test 457, 481
- EFG1 mutations 378
- Ekbom syndrome 370
- Elderly, *see* aging
- electrical activity, adaptation 14
- electromyography (EMG) 82–85
insertional and spontaneous activity 82–83
macro 88–89
motor unit morphology 84–85
motor unit recruitment 85, 86
needle 82–83
quantitative 89
single-fiber (SFEMG) 87–88
- electron microscopy 128–148

- electron transferring flavoprotein (ETF) 69, 405
- electron transferring flavoprotein:ubiquinone oxidoreductase (ETF:QO) 69, 405
- gene (*ETFDH*) mutations 405
- electrophysiological tests 81–91, 185–186
- disease signatures 89–91
- emerin (EMD) 64, 65–66, 300, 303
- gene mutations 65, 302, 305
- immunodetection 116–117, 306
- null mouse 66
- Emery–Dreifuss muscular dystrophy (EDMD) 299, 300–307
- autosomal dominant (AD EDMD; EDMD2) 65–66, 300
- autosomal recessive (AR EDMD; EDMD3) 300, 305
- clinical features 300, 305
- diagnosis 306
- future perspectives 310–311
- genetic counseling 306–307
- genotype–phenotype correlations 305–306
- management 306
- molecular basis 300–305
- mouse models 66
- MRI 155
- muscle biopsy 116–117, 133–134, 306
- X-linked (XL EDMD; EDMD1) 65–66, 300
- EMG, *see* electromyography
- end-plate potential (EPP) 453
- endocrine myopathies 175, 471–473
- endomysium 4–5
- energy metabolism 67–70, 390
- enlargement, muscle 171–172, 173
- β -enolase deficiency 394–395
- enzyme assays 187
- enzyme histochemistry 97–99, 101
- eosinophilia–myalgia syndrome 428, 443, 478
- eosinophilic fasciitis 443
- eosinophilic polymyositis 443
- eosinophilic syndromes 443
- ephedrine 467
- epidermolysis bullosa simplex and muscular dystrophy (EBS-MD) 63
- epilepsy and ataxia, autosomal recessive 371
- episodic ataxia type I (EA-I) 419–421
- Escobar syndrome 47, 463
- etanercept 457
- ethanol abuse 475, 478–480, 503
- examination, physical 177–183
- children 182–183
- inspection and palpation 177–178
- muscle 177–183
- neurological 177
- percussion 181
- reflex testing 181–182
- strength assessment 178–181
- exercise
- adaptation to 12–13
- energy sources 67, 390
- induced pain 168, 169
- intolerance
- fatty acid oxidation defects 396–401, 406
- glycogenoses 392–395
- periodic paralysis 418
- therapy 357, 381
- exercise testing 89, 90, 187–188, 394, 395
- exon skipping approach 198
- experimental autoimmune myasthenia gravis (EAMG) 454, 481
- extracellular matrix (ECM) 4–5
- electron microscopy 145–147
- protein defects 263–273
- protein immunohistochemistry 105
- regulation of satellite cells 25, 26
- eye problems 174
- facioscapulohumeral dystrophy 319
- myotonic dystrophy 356
- symptoms 166–167, 175
- see also* ocular muscle weakness
- F-actin, *see* actin, filamentous
- facial weakness 178–179
- facioscapulohumeral muscular dystrophy (FSHD) 314–319
- clinical features 314–315, 316
- diagnosis 317, 318
- genetic counseling 319
- genotype–phenotype correlations 317–318
- histopathology 117, 317
- management 316, 318–319
- molecular DNA testing 316–317, 318
- molecular genetics and pathogenesis 316–317
- MRI 155–156
- family history 176–177
- fascicles, muscle 5
- fast-channel syndrome 47, 463
- fatigue 171, 181
- fatigue index 9
- fatty acid β -oxidation defects 69, 396–407
- clinical features 397, 401, 403
- genetic counseling and prenatal diagnosis 406
- investigations 391, 405–406
- management 406–407
- molecular genetics 399
- muscle biopsy 122, 140–141, 402, 405–406
- pathophysiology 396–401
- fatty acid metabolism 67–69, 390, 401
- fetus
- akinesia 47, 273
- muscle biopsy 94
- FHL1 (SLIM1) 61, 294
- fibrates 476
- fibrillation potentials 82–83
- fibroblast growth factors (FGFs) 26–27
- fibroblasts, cultured 94
- fibrosis 28
- electron microscopy 145–147
- light microscopy 95, 96, 105
- therapeutic interventions 199–200
- filamentous inclusions
- intranuclear, *see* intranuclear inclusions
- tubular, *see* tubulofilaments
- filamin C 63
- gene mutations 486–489
- filaminopathy 63, 485
- muscle imaging 489
- FKRP, *see* fukutin-related protein
- flesh-eating disease 442
- fluoxetine 463, 467
- force of muscle contraction, control 11–12, 13
- force–time curves 12
- forearm exercise test 187, 394
- FRG1* 317
- fukutin 38–40, 258
- gene mutations 249, 257–258, 260
- genotype–phenotype correlations 261
- fukutin-related protein (FKRP) 247
- gene mutations 38–40, 247, 257–258, 260–261
- genotype–phenotype correlations 247–248, 261
- Fukuyama type congenital muscular dystrophy (FCMD) 257–262
- clinical features 259–260
- diagnosis 258–259
- genotype–phenotype correlations 261
- functional tests, bedside 180–181
- fusimotor (gamma) motor neurons 1–2
- gastrointestinal involvement 175, 356
- gastroparesis 356
- GCN triplet repeats 341–342, 343
- GDF8, *see* myostatin
- gene
- mRNA transcript, therapeutic manipulation 198
- replacement therapy 197–198
- translational interference 198
- gene defects
- direct therapeutic correction 198
- phenotypic heterogeneity 191
- types 189
- gene therapies, *see* molecular therapies
- genetic diagnosis, molecular 93, 188–189
- germanium 478
- glucose
- as energy source 67, 390
- intravenous, fatty acid oxidation defects 406
- metabolism 67, 68, 390
- α -glucosidase (acid maltase) 395
- deficiency, *see* Pompe disease
- X-linked vacuolar myopathy with normal, *see* Danon disease
- glutaric aciduria type II (GAI), *see* multiple acyl-CoA dehydrogenase deficiency
- glycogen
- electron microscopy 137
- granules (glycosomes) 4, 66–67
- histology 97
- metabolism 67, 68, 69
- glycogen storage disease 0 137, 396
- glycogen synthase 67, 396
- glycogenin 67

Index

- glycogenoses 391–396
 associated with weakness 395–396
 electron microscopy 137
 with exercise-induced symptoms 392–395
 histopathology and immunoanalysis 121–122
 molecular and biochemical basis 67, 68
 type II, *see* Pompe disease
 type IV, *see* brancher deficiency
 type VII, *see* phosphofructokinase (PFK) deficiency
 type VIII, *see* phosphoglycerate kinase (PGK) deficiency
 type IX, *see* phosphoglycerate kinase (PGK) deficiency
 type X, *see* phosphoglycerate mutase (PGAM) deficiency
 type XI, *see* lactate dehydrogenase (LDH) deficiency
- glycolysis 67, 68
 disorders of 121, 137
- glycosyltransferases 37–38
- GNE, *see* UDP-N-acetylglucosamine 2 epimerase/N-acetylmannosamine kinase
- GNE gene mutations 333–334, 492, 493
- GNE-related hereditary inclusion body myopathy (HIBM) (quadriceps-sparing myopathy) 430, 492–496
 animal model 494
 clinical features 429, 494
 diagnosis 492, 493, 495
 distal myopathy with rimmed vacuoles and 333–334, 492
 genetic counseling 495–496
 genotype–phenotype correlation 494–495
 imaging 158–159, 334
 molecular basis 56, 333–334, 492, 493
 pathogenesis 493–494, 496
 pathology 123, 334, 493, 495
 treatment 495
- goats, myotonic 410–411
- Golden Retriever Muscular Dystrophy (GRMD) dog 43, 211
- Golgi apparatus 66–67
- Gömöri trichrome 94
- GRACILE syndrome 377
- graft-versus-host reaction 444
- granulomatous myopathy 433, 442, 504–505
- growth, muscle 29
- growth factors (GFs) 26–27
- growth hormone deficiency 473
- hearing impairment 318, 381
- heart disease 172–173, 174
 Andersen–Tawil syndrome 416–417
 Emery–Dreifuss muscular dystrophy 305
 fatty acid oxidation defects 401
 inflammatory myopathies 430
 limb-girdle muscular dystrophies 235–236, 238, 244
 myotonic dystrophy 355–356, 356–357
see also cardiomyopathy
- hematoxylin and eosin (H&E) 94
- heparin sulfate (HS) proteoglycans 25, 26, 414
- hepatocyte growth factor (HGF) 27
- hereditary inclusion body myopathies (HIBM) 429–430, 492–496
 myosin mutations 60
 other conditions 496
 with Paget disease and frontotemporal dementia (IBMPFD) 347, 430, 496
 quadriceps sparing, *see* GNE-related hereditary inclusion body myopathy
- hereditary myopathies 183, 191
 classification 189–191
 genotypic heterogeneity 190–191
 phenotypic heterogeneity 191
- HIBM, *see* hereditary inclusion body myopathies
- histochemistry 94–102
- histology 94–102
- histopathology 93–124
- history 163–177
 family 176–177
 past medical 175–176
 presenting complaint 163–172
 social 177
 systemic symptoms 172–175
- HIV-associated myositis 441
- HLA-G 438
- HLA haplotypes, inclusion body myositis 429
- Hoffman syndrome 471
- HSPG2 gene mutations 414
- human T cell lymphotropic virus (HTLV-I) 441
- Huntington disease (HD) 200
- Hutchinson–Gilford progeria syndrome (HGPS) 66
- hyaline body myopathy 60
- hydroxychloroquine 478
- hyperactivity states, muscle 169–171
- hyperaldosteronism, primary 472
- hyperbaric oxygen 28
- hypercalcemia 502
- hyperCKemia 54, 186, 237
- hyperkalemic periodic paralysis (HyperPP) 58, 416
see also periodic paralysis
- hyperparathyroidism 472–473, 501–502
- hyperpolarized after-potentials (AHPs) 10
- hypersensitivity vasculitis 442
- hypersomnolence 355, 357
- hyperthyroid myopathy 471
- hypertrophy, muscle 29, 95, 171–172, 499
 disorders causing 172
 fiber-type specific 100–101
 therapeutic induction 199
- hypocalcemia 473, 502
- hypokalemic myopathies, drug-induced 478
- hypokalemic periodic paralysis (HypoPP) 58, 415–416
see also periodic paralysis
- hypoparathyroidism 473, 501–502
- hypopituitarism 473
- hypothyroid myopathy 471
- I-band 5, 59, 128
- imaging, diagnostic 151–160, 188
see also magnetic resonance imaging
- immobilization 500
see also disuse
- immunoanalysis 93–124
- immunoblot analysis 100, 107–108
- immunohistochemistry 102–107
 developmentally regulated proteins 102–103
 primary protein defects 103–104
 secondary protein defects 104–107
- immunological synapses 439
- immunosuppressive therapy
 inflammatory myopathies 446
 myasthenic disorders 457, 459
- inclusion body myopathies, hereditary, *see* hereditary inclusion body myopathies
- inclusion body myositis (IBM; sporadic inclusion body myositis; s-IBM) 427
 clinical features 427–428, 429–430
 diagnosis 431
 electron microscopy 133, 134, 136–137, 138, 143, 144, 145, 434
 extramuscular features 430–431
 familial inflammatory 429
 immunopathogenesis 437–441
 MHC-I expression 434
 MRI 159–160
 muscle pathology 99, 106, 123–124, 431–435
 treatment 445–447
- infantile polymyositis with sick myonuclei 444–445
- inflammatory cells
 electron microscopy 143, 144
 light microscopy 99, 102, 124
- inflammatory myopathies (IM) 427–447
 children 444–445
 clinical features 427–431
 collagen vascular diseases 442
 combined mitochondrial myopathy 444
 congenital 445
 diagnosis 184, 431–435
 drug-induced 428, 443–444, 478
 electron microscopy 143, 144
 EMG findings 431
 etiology and pathogenesis 435–441
 extramuscular features 430–431
 idiopathic (IIM) 427
 localized forms 443
 MHC-I expression 106, 434
 MRI 159–160
 muscle-derived serum enzymes 431
 muscle pathology 99, 123–124, 431–435
 with pipe-stem capillaries 443
 secondary 427
 serum autoantibodies 437
 statin-induced 476
 treatment 445–447
see also dermatomyositis, inclusion body myositis, polymyositis
- inherited myopathies, *see* hereditary myopathies
- injections, intramuscular 474

- injury, muscle 27–28
- innervation ratios 6–7
- insulin-like growth factor-1 (IGF-1) 27, 503
- insulin receptor (IR) 352
- integrin- α 7-deficiency 45, 115, 262
- integrin- α 7 β 1 45, 51, 211, 262
- integrins 4–5, 45
- intellectual impairment 174, 318
- intensive care unit (ICU) patients 477
- interdigitated muscles 5
- interferon- α / β 436–437
- interferon-induced myopathy 478
- intermediate filaments 3–4, 61–62
- intramuscular injections 474
- intranuclear inclusions (INI) 341–342, 343
- intranuclear rod myopathy 291
- intravenous immunoglobulin (IVIg) 446–447, 457, 459, 495
- ion channelopathies 57–59, 185, 409–421
- ion channels 3, 4, 56–59
- Isaac syndrome (acquired neuromyotonia) 420, 459–460
- jitter 87–88
- joint hyperlaxity, autosomal recessive congenital muscular dystrophy with 273
- KAL-1 protein 436
- Kearns Sayre syndrome (KSS) 368
- kidneys 175
- King–Denborough syndrome 58
- Kocher–Debre–Semelaigne syndrome 471
- laboratory investigations 183–189
- lactate 373, 394
- lactate dehydrogenase (LDH) deficiency 394–395
- Laing myopathy 332–333
clinical features 332
imaging 158, 333
molecular basis 60, 332
pathology 130, 333
- Lambert–Eaton myasthenic syndrome (LEMS) 48, 458–459, 501
- electrophysiological studies 86–87, 459, 501
- non-paraneoplastic (NP-LEMS) 458, 459
- paraneoplastic (P-LEMS) 458, 459
- lamin(s) 64–65, 300–302, 303
- lamin A/C mutations (laminopathies) 65–66
early onset phenotype 273–274
- Emery–Dreifuss muscular dystrophy 302–303, 305–306
- immunohistochemistry 116–117
- LGMD1B 235–237
- mouse models 66
- phenotypic heterogeneity 191, 235, 305
- lamina densa 142–143
see also basal lamina
- lamina lucida 142–143
- laminin(s) 4–5, 51
dystroglycan binding 42, 51
- immunohistochemistry 105–106, 114–115
- structure 52
- laminin- α 2 deficiency (MDC1A) 263–268
clinical features 263, 264
diagnosis 263, 264–265
genotype–phenotype correlations 264
management 265
- mini-agrin overexpression 52, 53
- molecular basis 50–52, 263
- mouse models 51–52
- muscle biopsy 103–104, 105–106, 114–115, 264–265
- muscle hypertrophy with secondary (MDC1B) 276
- prenatal diagnosis 115, 265
- laminopathies, *see* lamin A/C mutations
- LAMP-2 56, 294
Deficiency, *see* Danon disease
- gene mutations 56
- LAP2 64
- LAP2 α mutations 65
- LARGE 38–40, 249
gene mutations 257–258
- Largemyd mouse 258, 262
- laxatives 478
- Leber hereditary optic neuropathy (LHON) 370, 381
- Leigh syndrome (LS) 370, 373
- LEM domain family proteins 64
- LGMD, *see* limb-girdle muscular dystrophies
- licorice (liquorice) 478
- lid-lag sign 409, 411
- limb-girdle muscular dystrophies (LGMD) 230–250
autosomal dominant (AD) 111, 230, 234–239
autosomal recessive (AR) 111–113, 230, 239–249
classification 230–232
diagnosis 232–234, 250
future therapies 250
genetic counseling 234
histopathology and immunoanalysis 98, 111–113
management 232–234
molecular basis 230–232
MRI 152–154
prevalence 232
type 1A (LGMD1A) 63, 111, 234–235
type 1B (LGMD1B) 65, 66, 111, 235–237
type 1C (LGMD1C) 54, 111, 237
type 1D (LGMD1D) 111, 238
type 1E (LGMD1E) 111, 238
type 1F (LGMD1F) 111, 238
type 1G (LGMD1G) 111, 238–239
type 2A (LGMD2A), *see* calpainopathy
type 2B (LGMD2B) 53, 111, 112, 241–242
see also dysferlinopathies
type 2C–2F,
see sarcoglycanopathies
type 2G (LGMD2G;
telethoninopathy) 112, 244–246, 247
type 2H (LGMD2H) 60–61, 112, 246, 294
type 2I (LGMD2I) 245, 246–248, 260–261
molecular basis 39, 247
MRI 153, 154
pathology 100, 102, 112–113
see also
 α -dystroglycanopathies
type 2J (LGMD2J) 61, 113, 249, 327
type 2K (LGMD2K) 113, 248–249
type 2L (LGMD2L) 113, 249
type 2M (LGMD2M) 113, 249
type 2N (LGMD2N) 249
- limb-girdle myasthenic syndrome (LG-CMS)
DOK7 gene mutations 465
with tubular aggregates 465
- limb-girdle pattern of weakness 164, 165, 195
- limb muscles, strength assessment 180–181
- limbic encephalitis (LE) 460
- limit dextrin 67, 69
- linker of nucleoskeleton and cytoskeleton complex (LINC) 64
- lipid-lowering agent myopathies 168, 476–477
see also statin myopathy
- lipid metabolism 67–69
disorders, *see* fatty acid β -oxidation defects
- lipid storage myopathy 401, 402, 405–406
electron microscopy 140–141
- lipofuscin 134
- lipomatosis 175, 176
- lithium 478
- liver 173–174
- lobulated fibers 98, 99
- long-chain acyl-CoA dehydrogenase (LCAD) 69
deficiency 397, 405
- long-chain L-3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency 397, 399, 404, 406
- long QT syndrome 7 (LQT7) 416–417
- low-density lipoprotein receptor-related protein 4 45–46
- low energy laser irradiation (LELI) 28
- LRPPRC mutations 377
- Luft disease 363
- lung disease, inflammatory myopathies 430, 437
- lysosomal-associated membrane-2 protein, *see* LAMP-2
- lysosomal diseases 55, 134–137
- M-bands 3, 5, 59
- M-cadherin 22
- M-CAM (CD56) 22
- macrophages 102
- macrophagic myofasciitis 143, 145, 443, 478
- magnetic resonance imaging (MRI) 151–152, 152–160, 188
- magnetic resonance spectroscopy (MRS) 152, 188, 395

Index

- major histocompatibility complex, *see* MHC
- malignant disease
cachexia 500
carcinomatous myopathy 500–501
dermatomyositis 430–431
Lambert–Eaton myasthenic syndrome 458, 459, 501
muscle wasting disorders 500–501
peripheral nerve hyperexcitability syndromes 460
- malignant hyperthermia (MH) 475
periodic paralysis and 419
risk factors 58, 289, 293, 475
RYR1 mutations 70
susceptibility testing 475
- Mallory body-like inclusions 275
- Mallory body myopathy 71, 294
- MAN1 64
- ManNAc (*N*-acetylmannosamine) 493, 495
- O*-mannosyl glycosylation, disorders of, *see* α -dystroglycanopathies
- manual muscle testing 180
- Marinesco–Sjögren syndrome (MSS) 134, 503–504
- masseter weakness 178
- McArdle disease (myophosphorylase deficiency; glycogenosis V) 392
diagnosis 394–395
molecular therapies 198
muscle pathology 118, 119, 121, 137, 394
- mdm mouse 61
- mdx* mouse 43, 211
caveolin-3 overexpression 54
transgene studies 212
- medium-chain 3-ketoacyl-CoA thiolase (MCKAT) deficiency 397, 399, 405
- medium-chain acyl-CoA dehydrogenase (MCAD) 69
deficiency 396, 397, 399, 405
- medium-chain triglycerides (MCT) 406–407
- MELAS (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes) 370, 373
- membrane trafficking and repair proteins 53–56
- menadione-linked α -glycerophosphate dehydrogenase 101
- mental retardation, *see* intellectual impairment
- merosin deficiency, *see* laminin- α 2 deficiency
- MERRF (myoclonic epilepsy with ragged-red fibers) 370
- mesangioblasts 32–33, 199
- metabolic myopathies 120–123, 390–407
clinical presentations 390, 391
diagnostic testing 184–185, 187, 390, 391
MRI 159
- metalloproteinases 439
- methotrexate 446, 505
- methylprednisolone 445
- mexiletine 419
- MHC class I (MHC-I)
immunostaining 100, 106, 434
upregulation 440, 438
- microbial myositis, nonviral 442
- microcephaly–cortical dysplasia–peripheral neuropathy 276
- microtubules 61
- mighty gene 26
- miniature end-plate potential (MEPP) 453
- minicores 284, 286
- misery, dermatomyositis 428
- mitochondria 4, 66–67, 137–138, 364–365
aging changes 140
biogenesis 365
electron microscopy 137–140
electron transport–oxidative phosphorylation system 69, 365
fatty acid β -oxidation 390, 401
genetics 365–368
secondary abnormalities 363–364
structure and morphology 364–365
- mitochondrial disorders 69–70, 363–382
abbreviations 364
classification 363
clinical investigations 371–375
clinical presentation/syndromes 368–371
CNS and eye symptoms 174
combined inflammatory myopathy 444
drug-induced 477–478
- electron microscopy 137–140, 374
epidemiology 364
histopathology 98–99, 121, 122–123, 373–374
imaging 159, 373
late-onset myopathy 140
management 380–382
molecular diagnosis 375–380
mtDNA defects 363, 372, 375–376, 380–381
myopathic features 368
nuclear-genetic 363, 372, 376–380, 381
prenatal diagnosis 381
respiratory chain biochemistry 374–375
see also respiratory chain disorders
- mitochondrial DNA (mtDNA) 69, 365–368
depletion syndromes 379–380
heteroplasmy and threshold expression 366
mitotic segregation 368
multiple deletion syndromes 380
mutations 70, 363, 372, 375–376, 380–381
replication 366
secondary abnormalities 363
structure, genetic code and organization 365–366
transcription 366
translation 367
transmission 367–368
- mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) 370, 373
- mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE) 370
- mitochondrial recessive ataxia syndrome (MIRAS) 371
- mitochondrial trifunctional protein (MTP) deficiency 69, 397, 399, 404
- mixed rod–core myopathies 288, 291–292
- Miyoshi myopathy (MM) (distal dysferlinopathy) 334–336
clinical features 335
diagnosis 334, 335
imaging 157, 158, 335
molecular basis 53, 242, 334–335
pathology 112, 335
- molecular basis of disease 37–72
- molecular genetic diagnosis 93, 188–189
- molecular therapies 196–200
definitions 196
dominant diseases 200
indications 196
recessive diseases 197–200
types 196
- Morvan syndrome 460
- mosaicism, facioscapulohumeral muscular dystrophy 317–318
- motor nerve conduction studies 81
- motor neurons 1–2
axons 2
firing rates and patterns 12
motor unit type-related differences 10–11
synaptic specializations 10–11
types 1–2
- motor unit(s) 1–14
age-related remodeling 500
anatomy 1–6
control of muscle force 11–12, 13
EMG morphology 84–85
FF 9, 10, 11–12
F(int) or FI 9
FR 9, 10, 11–12
functional organization 6–11
human muscles 9–10
innervation ratios 6–7
recruitment 11–12, 85, 86
S 9, 10, 11–12
topographical territories 6
types 8–9
functional correlates 10
motor neurons and synaptic specializations 10–11
plasticity 12–14
- motor unit potentials (MUP) 84–85
- mounding-phenomenon 181
- mouse models
dysferlin deficiency 53–54, 335
dystroglycanopathies 39–40
dystrophinopathies 43, 211
hereditary inclusion body myopathy 494
laminin- α -2 deficiency (MDC1A) 51–52
myotonia congenita 410–411
myotonic dystrophy 66
myotubular myopathy 54–55
sarcoglycanopathies 41
titin deletions 61
- MPV17 mutations 379
- MRC muscle strength scale 180
- Mrf4 22
- MrpL32 378
- MRPS16 and MRPS22 mutations 378

- MSH2 and MSH3 mismatch repair proteins 348
- multi-minicore disease (MmD) 292–293
molecular basis 70–71, 292–293
MRI 156
muscle biopsy 131, 132, 286, 292
- multiple acyl-CoA dehydrogenase deficiency (MADD) 397, 399, 405
molecular and biochemical basis 69
riboflavin-responsive (RR-MADD) 141, 405, 406–407
- muscle(s)
anatomy 5–6
architecture 5
development 20–21
examination 177–183
interdigitated 5
pinnate 5
working lengths 5–6
- muscle ankyrin repeat proteins (MARPs) 61
- muscle biopsy 93–94, 188
enzyme assays 187
fetal 94
methods 93–94
selection of site 93
tissue preparation 94
- muscle contraction 3, 59
- muscle enlargement 171–172, 173
- muscle eye brain disease (MEB) 257–262
clinical features 260
diagnosis 258–259, 261–262
molecular basis 39, 258
- muscle fiber(s)
anatomy 3–4
arrangement in muscles 5
basement membrane 48–53
cytoskeleton 3, 61–64
denervation and reinnervation 13–14
density 88
differentiation 21
distribution in motor units 6–7
shape variations 95
size variation 95
splitting 95, 98
- muscle fiber types 7–8
energy metabolism 67
functional correlates 10
grouping 101, 108
hybrid 8
identification 96, 97–98, 99–100, 106
motor unit type associations 8–9
- pathology specific to 100–101
plasticity 12–14
predominance 108
type 1 (SO) 7, 12
type 2 7–8
type 2A (FOG) 7–8
type 2B 8
type 2C 8
- muscle LIM proteins (MLP) 61
- muscle nerves 1
- muscle RING finger proteins (MURFs) 61
- muscle-specific kinase, *see* MuSK
- muscle tension 5–6
passive contributions 5–6
- muscle unit 1
- muscle wasting, *see* wasting, muscle
- muscleblind-like protein 1 (MBNL1) 66, 352, 353
- muscleblind-like proteins (MBNL) 351, 352
- muscular dystrophies
cell therapy 30–31, 32–33
classification 192, 193
diagnostic testing 184
early childhood onset, *see* congenital muscular dystrophies
histopathology and immunoanalysis 108–118
MRI 152–156
with proximal weakness, *see* limb-girdle muscular dystrophies
see also specific dystrophies
- MuSK (muscle-specific kinase) 45–46, 47–48, 463
autoantibodies 48, 454–455, 456
gene mutations 465
- mutations, *see* gene defects
- MxA protein 436
- myalgia, *see* pain, muscle
- myalgia cruris epidemica 444
- myasthenia
congenital, *see* congenital myasthenic syndromes
drug-induced 479, 480–482
prenatal 463
- myasthenia gravis (MG) 48, 453–457
with AChR antibodies (AChR-MG) 453–454
avoidance of drug complications 481–482
clinical features 455–456
diagnosis 456–457
- differential diagnosis 417
drug-induced aggravation 479, 481
drug-induced unmasking 479, 481
electrophysiological studies 86–87, 88, 456–457
experimental autoimmune (EAMG) 454, 481
with MuSK antibodies (MuSK-MG) 454–455, 456
neonatal 455
ocular, 455–456
pathogenesis 453–455
seronegative (SNMG) 455
treatment 457, 458
- mycophenolate mofetil 446, 457
- Myf5 22, 23, 24
- MYH7 gene mutations 60, 294, 332–333
- MYHC2A gene mutations 60
- myoadenylate deaminase (MAD) 101
deficiency 122
- myoblast transfer therapy (MTT) 30–33
- myoblasts 20, 21
conversion of non-myogenic cells into 31–32
markers 23
plasticity 25
regenerating muscle 28
source in adult muscle 21–22, 31
- myoclonic epilepsy with ragged red fibers (MERRF) 370
- myoclonus–dystonia syndrome 243
- MyoD 22, 23, 500
- myodystrophy mouse (Largemyd) 258, 262
- myoedema 181
- myoferlin 53
- myofibers, *see* muscle fiber(s)
- myofibrillary myopathies (MFM) 62, 484–490
clinical phenotypes 484–485
diagnosis 484, 485–489
electron microscopy 130–131, 486, 488, 489
filaminopathy subset 63, 485
genetic counseling 490
genotype–phenotype correlations 484
imaging 159, 489
LGMD1A overlap 234–235
mutation analysis 486–489
myotilinopathy subset 63, 330, 485
- pathology 106, 121, 123, 485–486, 487
treatment and prevention 489–490
see also α B-crystallinopathy, desminopathies, ZASPopathy
- myofibrils 3
annular 131, 132
electron microscopy 128–131
- myogenesis
aging muscle 30
embryonic development 20–22
factors regulating 25–27
genetic regulation 22, 23
muscle regeneration 27–28
- myogenic precursor cells 20–33
cell therapy 30–33
origin during development 20–21
see also myoblasts, satellite cells
- myogenic regulatory factors (MRFs) 22
- myogenin 22
- myoglobin 7
- myoglobinuria 172, 173, 396–401
drug-induced 474–475
management 406
muscle histology after 402, 406
paroxysmal 403
- myokymia 420
see also rippling, muscle
- myophosphorylase (muscle phosphorylase) 67, 69
deficiency, *see* McArdle disease
gene (PYGM) mutations 392
histochemistry 101, 119, 121
- myosin
actin crosslinking 3, 59
filaments 3, 5, 59, 128
immunohistochemistry 99–100, 102–103, 106
neonatal 100, 102–103, 106
- myosin heavy chain (MHC) 128
I 7
IIA 7–8
IIB 8
IIX (IID) 8
adaptation to exercise 12–13
gene mutations, *see* MYH7 gene mutations; MYHC2A gene mutations
hybrid muscle fibers 8
isoforms 7
- myosin-related myopathies 60, 120, 130
- myosin storage myopathy 60, 288, 294
electron microscopy 130, 131

Index

- myositis
benign acute childhood (BACM) 444
nonviral microbial 442
viral infections 441
see also inflammatory myopathies
- myostatin (MSTN) 26, 500
therapeutic inhibition 199
- myotilin 63
gene mutations 330–331, 486
- myotilinopathy
distal 159, 330–331
LGMD1A 234–235
muscle imaging 489
muscle pathology 487
myofibrillary myopathy 63, 330, 485
spheroid body myopathy 294, 330
- myotonia(s) 171, 409
acetazolamide-responsive 412
cold-sensitive 411–412
drug-induced 475
EMG features 83, 195
examination 181
exercise testing 89
grip 181, 182, 195
myotonia congenita 409
myotonic dystrophy 355, 357
non-dystrophic 409–413
anesthesia risks 412–413
diagnosis 410, 413
paradoxical 171, 411–412
percussion 83, 181, 182, 195
periodic paralysis with 416
potassium-aggravated 58, 412, 416
sodium channel 412, 413
- myotonia congenita 409–411, 413
autosomal dominant (Thomsen) 57, 409–410
autosomal recessive (Becker) 57, 409–410
exercise testing 89
molecular basis 57–58, 410–411
sodium channel mutations 410, 412
- myotonia fluctuans 412
- myotonia levior 410
- myotonia permanens 412
- myotonic dystrophy (DM) 347–358
anticipation 349–350
clinical features 353, 354
congenital 349–350, 353
diagnosis 347–348
exercise testing 89
future perspectives 357–358
genetic counseling 357
genetic heterogeneity 347
- molecular pathogenesis 66, 348–353
- multisystem involvement 355–356
- muscle histopathology 117, 355
- skeletal muscle involvement 354–355
- time course 353
- treatment 356–357
- type 1 (DM1) 347, 353
animal models 66, 351
instability of CTG repeats 348–350
molecular therapies 200
RNA-mediated disease 350–352
- type 2 (DM2) 347, 353
instability of CCTG repeats 350
RNA-mediated disease 353
- type 3 (DM3) 347
- myotubes 20, 21, 28
- myotubular/centronuclear myopathies (MTM/CNM) 54–55, 293–294
animal models 54–55
autosomal 293–294
dominant 55, 293–294
electron microscopy 133
histopathology and immunoanalysis 114, 119–120, 288, 293
recessive 55, 294
X-linked 293
- myotubularin 54–55, 293
NDUFA1 mutations 376
NDUFA11 mutations 376
NDUFA12L (B17.2L) mutations 377–378
NDUFAB1 mutations 377
NDUFBS1-8 mutations 376
NDUFV1-2 mutations 376
- nebulin (NEB) 59, 60
mutations 60, 336
distal myopathy 158, 290–291, 336
nemaline myopathy 289–290
see also distal nebulin myopathy, nemaline myopathy
- neck extensor myopathy, isolated (INEM) 167–168
- neck extensor weakness 167–168, 179–180, 195
- neck flexor weakness 179–180
- necrosis 27–28
electron microscopy 147–148
histological features 96
inflammatory myopathies 124
- necrotizing fasciitis 443
- necrotizing fascio-myositis, hyperacute 442
- Nelson's syndrome 472
- nemaline bodies (rods) 60, 118, 284, 286, 289
- nemaline myopathy (NM) 285, 289–290, 336
electron microscopy 128–129, 134
histopathology and immunoanalysis 110, 118, 289
molecular basis 60, 284, 289–290
MRI 156–157
related disorders 290–292
- neonatal myasthenia gravis (NMG) 455
- neostigmine 481
- nerve conduction studies 81–82
- nesprin-associated congenital muscular dystrophy 274
- nesprins 64, 274
- nestin 23
- neurogenic disorders
electron microscopy 143, 144
histopathology and immunoanalysis 108
- neuroleptic malignant syndrome 475
- neurological examination 177
- neuromuscular junction (NMJ) 45–48, 453
anatomy 2–3, 4–5, 46
autoimmune diseases 48
formation 45–46
ion channels 3, 4
postsynaptic defects 47–48
postsynaptic membrane 46, 453
presynaptic defects 46, 47
synaptic defects 46, 47
- neuromuscular transmission 46–47, 453
autoimmune diseases 453–460
disorders 453–468
drug-induced disorders 480–482
inherited disorders, *see* congenital myasthenic syndromes
- neuromyotonia 48
acquired (Isaac's syndrome) 420, 459–460
clinical features 171
episodic ataxia type I and 419–421
familial isolated 420
- neuropathy, ataxia and retinitis pigmentosa (NARP) 370
- neurophysiological tests, *see* electrophysiological tests
- nicotinamide adenine dinucleotide dehydrogenase tetrazolium reductase (NADH-TR) 96, 97–98, 122–123
- nicotinic acid 476
- nitric oxide synthetase, neuronal (nNOS) 43–44, 104, 210–211
- NKX2-5 352
- non-thyroidal hypermetabolism 363
- Nonaka myopathy, *see* distal myopathy with rimmed vacuoles
- Notch signaling 22, 24, 30
- nuclear envelope 64–66, 303
- nucleus (nuclei)
central 96, 133, 284, 286, 293
electron microscopy 132–134
internal 95–96, 133
proteins 66
- Numb 22, 24
- nutritional myopathy 501–503
- obscurin (and obscurin-like protein) 61
- ocular disorders, *see* eye problems
- ocular muscle weakness 166–167, 195
assessment 178
see also ophthalmoplegia, ptosis
- oculopharyngeal muscular dystrophy (OPMD) 341–344
diagnosis 341, 343
genetic counseling 344
genotype-phenotype correlations 342–343
management 344
molecular basis 341–342, 343
pathology 117–118, 133, 134, 342, 343
- Oil red O 94–95
- ophthalmoplegia 167, 178
myotubular/centronuclear myopathies 293
progressive external, *see* progressive external ophthalmoplegia
- oral foliate cells 94
- osteomalacia 473, 501–502

- oxidative phosphorylation (OXPHOS) 138, 365, 390
see also respiratory chain disorders
- oxidative stress 214
- p94, *see* calpain-3
- PABPN1, *see* polyadenylation binding protein nuclear 1
- PABPN1* gene defects 341–342, 343
- pain, muscle (myalgia) 168
 diffuse 168, 169
 drug-induced 474
 exercise-induced 168, 169
 focal and localized 168
 strength assessment and 180
see also pain
- paired helical filaments (PHFs), *see* tubulofilaments
- palatal weakness 179
- palpation, muscle 177–178
- paramyotonia congenita (PC) 411–412, 413, 416
 exercise testing 89, 412
 molecular basis 58, 412
- paraneoplastic syndromes 500–501
see also malignant disease
- paraplegin 378
- parasitic polymyositis 442
- pathology 93–124
- Pax3 22, 23
- Pax7 22, 23, 24, 30
- Pearson syndrome (PS) 370
- penetrance, variable 191
- D-penicillamine 444, 478
- pentazocine-induced myopathy 443
- PEO1*, *see* Twinkle helicase
- percussion, muscle 181
- perhexiline 478
- periarteritis nodosa 442
- pericytes 32–33
- periodic acid Schiff (PAS) 94–95, 97
- periodic paralysis (PP) 414–419
 anesthesia and 419
 differential diagnosis 417
 examination and laboratory tests 417
 genetic testing 417–418
 hyperkalemic (HyperPP) 58, 416
 hypokalemic (HypoPP) 58, 415–416
 molecular pathophysiology 418
- muscle histopathology 418
 neurophysiological tests 89, 90, 418
 thyrotoxic (TPP) 417, 419, 472
 treatment 418–419
- peripheral nerve hyperexcitability (PNH) syndromes, acquired 459–460
- peripheral nervous system diseases involving 174
 examination 177
 symptoms 174
- perlecan 52, 414
- phenytoin 444
- phosphofructokinase (PFK) deficiency (Tarui disease) 101, 121, 394–395
- phosphoglycerate kinase (PGK) deficiency 393, 394–395
- phosphoglycerate mutase (PGAM) deficiency 393–394, 394–395
- phosphorus magnetic resonance spectroscopy 188, 395
- phosphorylase, muscle, *see* myophosphorylase
- phosphorylase *b* kinase (PHK) 67
 deficiency 393, 394–395
- physical examination, *see* examination, physical
- pinnate muscles 5
- pipe-stem capillaries 144, 443
- pituitary disorders 473
- plasma membrane 142–143
- plasmapheresis (plasma exchange) 446, 457, 459
- plasmid gene vectors 197
- plectin 63
- POLG disease (*POLG* mutations) 379, 380
 clinical syndromes 370–371
- POLG* (*POLG1*) gene 363, 366
- polyadenylation binding protein nuclear 1 (PABPN1) 341–342, 343
- polymerase γ (*POLG*) 366
- polymyositis (PM) 427
 childhood 444–445
 clinical features 427–428, 428–429
 diagnosis 431–435
 drug-induced 478
 electron microscopy 143, 147
 eosinophilic 443
 extramuscular features 430–431
 immunopathogenesis 437–441
- infantile, with sick myonuclei 444–445
 localized 443
 MHC-I expression 434
 MRI 159–160
 muscle pathology 123–124, 431–435, 436, 437
 nonviral microbial 442
 treatment 445–447
 tropical 442
- Pompe disease (acid maltase deficiency) 56, 395
 MRI 159
 muscle pathology 120, 121–122, 135, 137, 395
- post-tetanic potentiation (PTP) 12, 13
- postoperative respiratory depression 479, 481
- postural myopathy, X-linked 61
- potassium-aggravated myotonia 58, 412, 416
- potassium channelopathies 59
KCNA1 mutations 419–421
KCNJ2 mutations 415, 416, 417–418
- potassium channels, voltage-gated (VGKCs) 420, 453
 autoantibodies 48, 460
- potassium chloride 418–419
- potassium-depleting drugs 478
- prayer sign 48–49
- prednisone 445–446, 457
- prenatal diagnosis 94
- prenatal myasthenia 463
- presynaptic defects 46
- procainamide 444
- progression, rate of 183
- progressive external ophthalmoplegia (PEO)
 autosomal dominant 371, 380
 autosomal recessive 371
 chronic 368
- prostigmine 457, 461
- protein aggregation myopathies 61
- protein defects
 classification based on 190
 primary 103–104
 secondary 104–107
 upregulation of functional analog 198–199
- protein *O*-mannose beta-1, 2-*N*-acetylglucosaminyl-transferase (POMGnT1) 38–40
 gene mutations 257–258
- genotype–phenotype correlations 261
 immunohistochemistry 115
- protein *O*-mannosyl transferase 1 (POMT1) 38–40
 gene mutations 249, 257–258
 genotype–phenotype correlations 261
- protein *O*-mannosyl transferase 2 (POMT2) 38–40
 gene mutations 249, 257–258
 genotype–phenotype correlations 261
- proteoglycans 4–5, 25, 26
see also agrin, perlecan
- proximal myotonic dystrophy (PDM), *see* myotonic dystrophy (DM), type 2
- proximal myotonic myopathy (PROMM), *see* myotonic dystrophy (DM), type 2
- pseudohypertrophy 171–172
- pseudouridine synthase 1 (*PUS1*) 378–379
- PTC124 198
- ptosis 166–167, 178, 455
 myasthenia gravis 455–456
 oculopharyngeal muscular dystrophy 341, 344
- purine nucleotide metabolism, disorders of 122
- PUS1* mutations 378–379
- pyomyositis 442
- pyridostigmine 457, 459, 461
- pyruvate 67
- quadriceps-sparing myopathy, *see* *GNE*-related hereditary inclusion body myopathy
- quinidine sulfate 463, 467
- ragged red fibers (RRF)
 electron microscopy 138, 139
 histochemistry 96, 121, 122–123, 374
- RAPSN* gene mutations 47, 462, 464, 465, 466
- rapsyn 45–46, 464
- recessive diseases, molecular therapies 197–200
- recruitment of motor units 11–12
 early 85, 86
 EMG features 85, 86
 reduced 85
 size principle 11
- reducing bodies 101, 120
- reducing body myopathy (RBM) 61, 294

Index

- reflex testing 181–182
- regeneration 27–28, 216
electron microscopy 147–148
histopathology 96, 106
impaired 28
therapeutic interventions 28, 199
transplanted muscle 28
see also necrosis
- reinnervation 13–14
- renal failure
acute 474–475
chronic 175, 502
- repeated sequences, deletions or expansions 117–118
- repetitive nerve stimulation (RNS) 85–87
- respiratory chain 69, 365
- respiratory chain disorders 69–70, 372, 375–376
assembly factor mutations 377–378
biochemical diagnosis 374–375
electron microscopy 139–140, 141
mitochondrial translation defects 378–379
mtDNA depletion syndromes 379–380
multiple enzyme defects 378
multiple mtDNA deletion syndromes 380
structural component defects 376–377
see also mitochondrial disorders
- respiratory depression, postoperative 479, 481
- respiratory failure 168
distal myopathy with 337
- respiratory function testing 181
- respiratory muscles
assessment 181
weakness 168, 195
- retroviruses 441
- revertant fibers 101, 109–110, 216, 217
- rhabdomyolysis
amyloid myopathy 503
drug-induced 474–475, 476
fatty acid β -oxidation defects 396–401
- rheumatoid arthritis (RA) 124, 442, 504
- riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency (RR-MADD) 141, 405, 406–407
- riboflavin supplements 405, 406–407
- ribonucleotide reductase (*RRM2B*) 379
- ribosomes, free 66–67
- ricketts 473
- rigid spine muscular dystrophy 1 (*RSMD1*) 71, 274–276
clinical features 275
histopathology and immunoanalysis 115–116, 275–276
MRI 154, 155
- rimmed vacuoles (RV) 135, 136–137, 138
inclusion body myositis 434
oculopharyngeal muscular dystrophy 343
- rippling, muscle 181, 195, 420
- rippling muscle disease 54, 171, 237
- rituximab 446, 457
- RNA splicing, abnormal 351–352, 353
- rod-core myopathies, mixed 288, 291–292
- ryanodine receptors (*RYR1*) 70–71
gene mutations 70–71
central core disease 292
centronuclear myopathy 294
multi-minicore disease 292
pathology 112, 119
localization 3, 56–57
- sag property 9, 12
- SANDO syndrome 371
- sarco/endoplasmic reticulum Ca^{2+} ATPase 1 (*SERCA1*) 71
- sarco/endoplasmic reticulum Ca^{2+} ATPase 2 (*SERCA2*) 71
- sarcoglycan–sarcospan complex 39, 40–41
- sarcoglycanopathies (LGMD types 2C–2F) 242–244
animal models 41
clinical features 243
diagnosis 243–244
genotype–phenotype correlations 244
management 244
molecular basis 40–41, 243
muscle biopsy analysis 107, 112, 216, 218, 243–244
- sarcoglycans 3, 40, 104–105, 210, 243
- sarcoid myopathy 124, 442, 504–505
- sarcolemma 3
electron microscopy 142–143
- ion channels 56–59
neuromuscular junction 45–48
trafficking and repair proteins 53–56
transmembrane proteins 45
- sarcomeres
proteins 59–61
structure 3, 5, 59
- sarcopenia, age-related 499–500
- sarcoplasm 66–70
- sarcoplasmic reticulum (SR) 3, 70–72, 141–142
- sarcospan 41
- sarcotubular myopathy 294
- satellite cells 5, 21, 22–30
aging muscle 30
atrophic muscle fibers 29
blood vessel-associated cells and 32–33
dystrophinopathies 215
electron microscopy 22–24, 147–148
factors regulating 25–27
genetic regulation 22, 23
growing or hypertrophic muscle 29
markers 22–24
plasticity 25
regenerating muscle 27–28
as source of myoblasts 21–22, 31
stem cell sub-population 24–25
- Sca-1 24
- scapulo-peroneal pattern of weakness 166, 195
- scapulo-peroneal syndrome 61, 496
(Stark–)Kaeser type 332, 484
- scatter factor (SF; HGF) 27
- Schwartz–Jampel disease (SJD) 52, 413–414
- scleroderma, *see* systemic sclerosis
- sclerotome 20
- SCN4A* mutations 58, 413, 465
myotonia congenita 410, 412
paramyotonia congenita 412
periodic paralysis 415, 416, 417–418
sodium channel myotonias 412
- SCO1* and *SCO2* mutations 377
- SDHA* mutations 376
- second wind phenomenon 392, 394, 395
- selenoprotein 1 (*SEPN1*) 58, 71–72, 274–275
- gene mutations 70, 71, 274–276
Mallory body myopathy 294
multi-minicore disease 292–293
pathology 113, 115–116, 119, 275–276
genotype–phenotype correlations 275, 284
immunoblot analysis 116
- sensory nerve action potentials (SNAPs) 81–82
- sensory nerve conduction studies 81–82
- serum biochemistry 186–187
- Sherrington, Sir Charles 1
- short-chain acyl-CoA dehydrogenase (*SCAD*) 69
deficiency 397, 399, 405
- short-chain L-3-hydroxyacyl-CoA dehydrogenase (*SCHAD*) deficiency 397, 405
- short interfering RNAs (siRNAs) 352
- short stature, mental retardation, distal laxity and congenital muscular dystrophy 276
- sialic acid 493–494, 495
- sialuria 493
- simple sequence repeats (SSRs) 348
- SLX5* gene 352
- SJL mouse 53–54
- Sjögren's syndrome 442, 504
- skeletal muscle, development 20–22
- skeleto-fusimotor (beta) motor neurons 1–2
- skin
biopsy 94
involvement 175
- SLC22A5* gene mutations 402
- sleep-related breathing disorders 357, 381
- slow-channel syndrome (SCCMS) 47, 462, 463, 466, 467
- small cell lung carcinoma (SCLC) 458, 460, 501
- social history 177
- sodium channel myotonias 412, 413
- sodium channels 58, 413, 418
blockers 411, 412, 414
gene mutations, *see* *SCN4A* mutations
voltage-gated (VGSC), neuromuscular junction 46, 453

- somites 20
- β -spectrin 104
- speech 179
- spheroid body myopathy 63, 294, 330
- sphingolipids 25
- spinal cord, motor neurons 1, 2
- spinal muscular atrophies (SMA) 95, 101, 108
- spironolactone 418–419
- spliceopathy 351–352, 353
- Stark–Kaeser scapuloperoneal syndrome 332, 484
- statin myopathy 168, 476–477
drugs increasing risk 477
hypothyroidism and 471
- stem cells 24–25
bone marrow-derived 32
lineage conversion 31–32
therapy 30–33
- steroid myopathy 475–476
- steroid therapy,
see corticosteroid therapy
- stiff-person syndrome 171
- stiffness 169–171
- strength assessment 178–181
cranial nerve innervated muscles 178–180
limb and trunk muscles 180–181
MRC scale 180
respiratory muscles 181
- streptococcus, group A
beta-hemolytic 442
- succinate dehydrogenase (SDH)
fiber typing 97–98
mitochondrial disorders 98, 99, 121, 122–123, 374
- SUCLA1* and *SUCLA2* mutations 380
- Sudan black 94–95
- SUN proteins 64
- SURF1* mutations 377
- swallowing, assessment 179
- synaptic defects 46
- synaptic specializations 10–11
- synaptogamin I, antibodies 459
- syntrophins 3, 43–44
- systemic lupus erythematosus (SLE) 124, 442, 504
- systemic sclerosis (SSc) 124, 442, 504
- systemic symptoms 172–175
- T cells
CD4+ 454
cytotoxic CD8+ 437–438, 438–439
- T regulatory (Treg) cells 454
- T-system networks 142, 143
- T-tubules 3, 56–57, 141–142
- tacrolimus 446, 457
- tafazzin 364
- target fibers 99, 108
- Tarui disease,
see phosphofructokinase (PFK) deficiency
- telethonin 60–61, 244
gene mutations 244, 245
immunoanalysis 245–246
- telethoninopathy (LGMD2G) 112, 244–246, 247
- temporalis muscles 178
- tendon reflexes 181–182
- thick filaments 3, 59
protein diseases 130
proteins 128
- thigh muscle infarction, diabetes 188, 473
- thin filaments 3, 59
protein diseases 128–130
proteins 60, 128
- Thomsen myotonia 57, 409–410
- thymectomy 457
- thymic hyperplasia 454
- thymidine kinase-2 (TK2) 379
- thymidine phosphorylase (ECGF1) 380
- thymoma 442, 454, 457, 460
- thyroid ophthalmopathy 472
- thyrotoxic periodic paralysis (TPP) 417, 419, 472
- tibial muscular dystrophy (TMD) 326–328
clinical features 327
imaging 158, 327–328
molecular basis 61, 326–327
- titin 3, 59, 60–61, 327
associated proteins 60–61
deletions, mdm mouse 61
mutations 61, 249, 293, 326–327
- titin myopathy with
cardiomyopathy,
congenital 61, 293
- TK2* gene mutations 379
- toluene 478
- tongue weakness 179
- total lymphoid irradiation (TLI) 446
- transforming growth factor-beta (TGF- β) superfamily 26
- translational interference 198
- transplantation, muscle 28
- transverse (T) tubules 3, 56–57, 141–142
- trauma, muscle 27–28
- triads 3, 56–57
- triamterene 418–419
- Trichinella* myositis 433
- TRIM32-related dystrophy (LGMD2H) 60–61, 112, 246, 294
- triple repeat expansion disorders 66
myotonic dystrophy 347, 348–353
oculopharyngeal muscular dystrophy 341–342, 343
- tropomyosin (Tm) 3, 59, 128
gene mutations 60, 289–290
isoforms 60
- troponin 3, 59, 60, 128
- trunk muscles, strength assessment 180–181
- tubular aggregates 142, 465
- tubulofilaments 137, 138, 433–434, 435
- Turner syndrome 206
- Twinkle helicase (*PEO1*) 366, 379, 380
- ubiquinone, *see* coenzyme Q
- Udd myopathy, *see* tibial muscular dystrophy
- UDP-N-acetylglucosamine 2 epimerase/N-acetylmannosamine kinase (GNE) 333–334, 492–494, 496
see also *GNE* gene mutations
- Ullrich congenital muscular dystrophy (UCMD) 268–273, 299–300, 307–310
clinical features 269, 271, 301, 308
diagnosis 269, 272, 309–310
future perspectives 310–311
genetic counseling 310
genotype–phenotype correlations 271–272, 308–309
management 272–273, 310
- molecular basis 48–50, 269–271, 307–308
MRI 154, 309
muscle biopsy 107, 115, 269, 270, 272, 309
prenatal diagnosis 115, 310
- ultrasonography (US) 151, 188
- ultrasound therapy 28
- ultrastructural studies 128–148
- UQCRB* mutations 376
- UQCRQ* mutations 376
- urine tests 186–187
- utrophin 44–45, 208
extrasynaptic, in dystrophinopathies 216–217, 219
immunohistochemistry 105, 110
therapeutic upregulation 199
- vacuolar myopathies, autophagic,
see autophagic vacuolar myopathies
- vacuoles
histopathology 102
rimmed, *see* rimmed vacuoles
- vascular endothelial growth factor (VEGF) 28
- vasolin-containing protein (VCP) 123
- VCP* gene mutation 347
- vectors, gene 197
- very long-chain acyl-CoA dehydrogenase (VLCAD) 69
deficiency 397, 399, 402, 404, 405, 406
- vincristine 478
- viral infections, myositis 441
- viral vectors 197
- vitamin D deficiency myopathy 473, 501–502
- vitamin E deficiency myopathy 502
- vocal cord and pharyngeal distal myopathy (VCPDM; MPD2) 337
- voltage-gated calcium channels,
see calcium channels,
voltage-gated
- Walker–Warburg syndrome (WWS) 257–262
clinical features 260
diagnosis 258–259, 261–262
molecular basis 258, 261
(WWS)-like syndrome 39

Index

- warm-up phenomenon 409
- wasting, muscle 171–172, 499
conditions causing 499–505
- weakness 163–168
assessment, *see* strength
assessment
children 182–183
give-way 180
glycogenoses associated with
395–396
inflammatory myopathies 427
myasthenic syndromes
455–456, 459
periodic paralyses 415
predominant patterns
164–168
- Welander distal myopathy
323–326
imaging 158, 326
- Western blotting,
see immunoblot analysis
- Wnt, aging muscle 30
- working lengths, muscle 5–6
- X-linked cardiomyopathy 111,
206, 212–213, 215
- X-linked myopathy with
excessive autophagy
(XMEA) 56
electron microscopy 136
histopathology and
immunoanalysis 122
- X-linked vacuolar myopathy,
see Danon disease
- Xp21 dystrophies,
see dystrophinopathies
- Xp21 translocations, females
with 111, 206
- Z-band alternatively spliced
PDZ-motif containing
protein, *see* ZASP
- Z-band streaming 131, 133
- Z-disks 3, 5, 59, 62, 128
pathology, myofibrillary
myopathies 486, 488
protein defects 62
proteins 59, 128
- ZASP 64, 107, 329
gene mutations 486
- ZASPopathy 328–330
clinical features 485
imaging 159, 329, 489
pathology 330
- zebra body myopathy 292
- zebrafish
RYR1 mutations 71
selenoprotein 1 mutations
71–72
- zidovudine-induced myopathy
441, 444, 477–478
- ZNF9* gene 347, 353